Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.0%
    Check dated 2025-08-18T02:16:32.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.0%
    Check dated 2025-08-11T00:11:35.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    0.4%
    Check dated 2025-08-03T17:58:42.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.1%
    Check dated 2025-07-27T14:33:45.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.0%
    Check dated 2025-07-20T11:41:43.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    The web page now includes a service alert regarding planned maintenance starting July 25th, indicating that most services will be unavailable for over 24 hours beginning at 9 PM EDT.
    Difference
    0.4%
    Check dated 2025-07-12T07:27:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.